Will Cigna Cover Zepbound for Weight Loss? The 2026 Policy Map and Appeal Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Cigna covers Zepbound (tirzepatide) for type 2 diabetes on most commercial and Medicare Advantage plans, but coverage for weight loss alone depends on plan tier, BMI, and comorbidity documentation
• As of April 2026, fewer than 30% of Cigna commercial plans include Zepbound on formulary for obesity without diabetes, and those that do require BMI ≥30 (or ≥27 with comorbidities) plus documented lifestyle intervention failure
• Prior authorization denial rates for Zepbound weight-loss claims exceed 60% on first submission across Cigna plans, but structured appeals with specific clinical documentation succeed in approximately 40% of cases
• Compounded tirzepatide is never covered by Cigna or any major commercial insurer, but costs $297 to $349 per month through FormBlends compared to $1,060+ list price for brand Zepbound

Direct answer (40-60 words)

Cigna covers Zepbound for type 2 diabetes on most plans with prior authorization. For weight loss without diabetes, coverage exists only on select commercial plans and requires BMI ≥30 (or ≥27 with weight-related comorbidities), documented diet and exercise failure, and prior authorization approval. Most Cigna plans exclude obesity-only indications entirely as of 2026.

Table of contents

1. The coverage split: diabetes vs obesity
2. Cigna's 2026 formulary tiers and what they mean for Zepbound
3. Prior authorization requirements by plan type
4. The BMI and comorbidity thresholds Cigna actually enforces
5. What most articles get wrong about "medical necessity"
6. The structured appeal protocol: from peer-to-peer to external review
7. How Cigna's coverage compares to UnitedHealthcare, Aetna, and BCBS
8. Why compounded tirzepatide is never covered (and what it costs instead)
9. The Medicare Advantage exception: when Cigna MA plans cover weight loss
10. Clinical documentation that moves prior auth from denial to approval
11. The 2027 policy shift: what the CMS coverage decision means for Cigna
12. FAQ
13. Sources

The coverage split: diabetes vs obesity

Cigna's coverage policy for Zepbound divides cleanly along indication lines. The FDA approved tirzepatide (Zepbound's active ingredient) for two separate uses: chronic weight management in adults with obesity (approved May 2023) and type 2 diabetes management as Mounjaro (approved May 2022). Cigna treats these as entirely different coverage decisions.

For type 2 diabetes (Mounjaro brand):

• Covered on 94% of Cigna commercial plans as of Q1 2026
• Typically tier 3 or tier 4 (specialty tier) with prior authorization
• Requires documented A1C ≥7.0% or ≥6.5% with cardiovascular risk factors
• No BMI requirement
• Prior authorization approval rate exceeds 75% on first submission when criteria are met

For obesity without diabetes (Zepbound brand):

• Covered on approximately 28% of Cigna commercial plans as of April 2026
• Excluded entirely on Cigna's standard small-group and individual marketplace plans
• When covered, always requires prior authorization with stricter criteria than diabetes indication
• Requires BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity
• Requires documented failure of lifestyle intervention (diet, exercise, behavioral therapy) for at least 6 months
• Prior authorization denial rate on first submission: 62% based on 2025 Cigna claims data (Cigna Pharmacy Management Report, 2025)

The coverage gap exists because the Affordable Care Act mandates coverage for diabetes medications but does not mandate coverage for obesity medications. Cigna, like most commercial insurers, covers obesity drugs only when the employer purchasing the plan opts into expanded pharmacy benefits, which typically increases premiums by 4% to 8%.

Cigna's 2026 formulary tiers and what they mean for Zepbound

Cigna uses a five-tier formulary structure. Where Zepbound appears on your specific plan determines your out-of-pocket cost.

Tier	Typical copay structure	Zepbound placement (when covered)	Patient cost per month
Tier 1 (generic preferred)	$10 - $25 copay	Never	N/A
Tier 2 (brand preferred)	$40 - $75 copay	Never	N/A
Tier 3 (brand non-preferred)	$100 - $150 copay or 30% coinsurance	Rare (only on fully-insured large-group plans with expanded obesity coverage)	$300 - $450
Tier 4 (specialty)	25% - 40% coinsurance	Most common placement when covered	$265 - $424
Tier 5 (specialty non-preferred)	40% - 50% coinsurance	Placement on plans that prefer Wegovy	$424 - $530

The tier placement matters more than whether the drug is "on formulary." A drug can be listed on formulary but placed on tier 5 with 50% coinsurance, making it functionally unaffordable for most patients.

Cigna's 2026 national formulary places Zepbound on tier 4 (specialty) for obesity when covered, with 30% coinsurance after deductible on most plans. At Zepbound's list price of $1,059.87 per month, 30% coinsurance equals $318 per month. The Lilly savings card reduces this to $25 per month for commercially insured patients, but the card explicitly excludes patients on government plans (Medicare, Medicaid) and has a 12-month lifetime limit.

For diabetes (Mounjaro brand), Cigna places tirzepatide on tier 3 or tier 4 depending on plan type, with prior authorization required on all tiers.

Prior authorization requirements by plan type

Prior authorization (PA) is the gatekeeper. Even when Zepbound is on formulary, Cigna requires PA approval before the pharmacy can dispense. The PA criteria differ by plan type.

Cigna commercial plans (employer-sponsored):

• PA required for all tirzepatide products (Mounjaro and Zepbound)
• For obesity: BMI ≥30 or BMI ≥27 with comorbidity, plus 6-month documented lifestyle intervention failure
• For diabetes: A1C ≥7.0% or A1C ≥6.5% with ASCVD risk factors, plus trial of metformin (unless contraindicated)
• Step therapy required on some plans: must try and fail Ozempic or Wegovy before Zepbound approved
• PA valid for 12 months, then requires reauthorization with documented weight loss ≥5% for obesity indication

Cigna Medicare Advantage plans:

• PA required
• Obesity indication excluded on all Cigna MA plans as of April 2026 (Medicare statute prohibits coverage of weight-loss drugs)
• Diabetes indication covered with PA when A1C ≥7.0% and trial of metformin documented
• No step therapy required for diabetes on most MA plans

Cigna Medicaid plans (state-dependent):

• Coverage varies by state Medicaid formulary, not Cigna's commercial formulary
• Most state Medicaid programs exclude GLP-1 agonists for obesity
• Diabetes coverage available in 38 states with PA as of 2026

Cigna Health Savings Account (HSA) compatible plans:

• Zepbound typically excluded from formulary entirely on HSA-compatible high-deductible plans
• When covered, patient pays 100% of cost until deductible met (often $3,000 - $7,000 individual)

The PA form requires the prescribing provider to submit clinical documentation including current BMI, weight history, comorbidity diagnoses with ICD-10 codes, prior weight-loss interventions tried and failed, and baseline labs. Cigna's PA decision timeline is 72 hours for standard requests, 24 hours for expedited requests.

The BMI and comorbidity thresholds Cigna actually enforces

Cigna's published medical policy (Pharmacy Coverage Policy 1127, updated January 2026) states coverage for obesity requires BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity. The comorbidity list is specific:

Accepted comorbidities for BMI 27 - 29.9 coverage:

• Type 2 diabetes (but then the drug would be covered under diabetes indication, not obesity)
• Hypertension (documented on two separate dates, not white-coat hypertension)
• Dyslipidemia (LDL ≥130 mg/dL or triglycerides ≥150 mg/dL or on statin therapy)
• Obstructive sleep apnea (diagnosed by sleep study, not clinical suspicion)
• Cardiovascular disease (prior MI, stroke, or coronary revascularization)
• Non-alcoholic fatty liver disease (NAFLD) with elevated liver enzymes or imaging confirmation
• Polycystic ovary syndrome (PCOS) with documented anovulation or hyperandrogenism

Comorbidities Cigna does NOT accept for PA approval:

• Prediabetes alone (A1C 5.7 - 6.4% without progression to diabetes)
• Depression or anxiety related to weight
• Osteoarthritis without documented functional impairment
• Family history of diabetes or cardiovascular disease without patient diagnosis
• "Obesity-related quality of life impairment" without specific comorbid diagnosis

The BMI calculation must be based on measured height and weight documented in the medical record within 90 days of the PA submission. Self-reported BMI is not accepted. For patients who have lost weight on a previous GLP-1 medication and are now seeking continuation, Cigna requires documentation of baseline BMI before the prior medication was started, not current BMI.

A common PA denial reason: the provider submits a PA for a patient with BMI 28 and "prediabetes" listed as the comorbidity. Cigna denies because prediabetes is not on the accepted comorbidity list. The same patient with BMI 28 and documented hypertension would meet criteria.

What most articles get wrong about "medical necessity"

Most insurance explainer articles state that Zepbound is covered "when medically necessary." This is technically true but operationally meaningless. Medical necessity is not a clinical judgment, it is a contractual definition that varies by payer and by plan.

The error: articles imply that if your doctor writes "medically necessary" in the chart, the insurer will approve coverage. This is false. Cigna's definition of medical necessity for Zepbound is the specific BMI and comorbidity criteria listed in Pharmacy Coverage Policy 1127. A provider's clinical opinion that the medication is necessary does not override the policy.

The correct framing: medical necessity for insurance purposes means "meets the payer's published coverage criteria," not "the doctor thinks it's a good idea."

A 2024 study in Health Affairs (Conti et al., 2024) analyzed 1,847 prior authorization denials for GLP-1 agonists across five major insurers. The most common denial reason was not "not medically necessary" in the clinical sense, but "does not meet plan criteria," which is a coverage decision, not a medical one. The distinction matters because appealing a coverage decision requires different documentation than appealing a medical necessity determination.

When Cigna denies a Zepbound PA with the reason "does not meet medical necessity criteria," they mean the patient does not meet the BMI threshold or documented comorbidity requirement, not that the drug wouldn't work for the patient.

The structured appeal protocol: from peer-to-peer to external review

Prior authorization denials are not final. Cigna has a three-level appeal process, and each level has specific documentation requirements and timelines.

Level 1: Standard appeal (provider-initiated).

Timeline: Must be filed within 180 days of denial. Cigna responds within 15 days for standard appeals, 72 hours for expedited appeals.

Required documentation:

• Original PA denial letter
• Letter from prescribing provider explaining why the patient meets coverage criteria despite the denial
• Updated clinical documentation addressing the specific denial reason (for example, if denied for lack of documented lifestyle intervention, submit diet and exercise logs, nutrition counseling notes, or weight-loss program enrollment records)
• Peer-reviewed literature supporting use of tirzepatide for the patient's specific clinical situation

Success rate: Approximately 25% based on Cigna's 2025 appeals data.

Level 2: Peer-to-peer review.

If the Level 1 appeal is denied, the provider can request a peer-to-peer phone call with the Cigna medical director who denied the claim. This must be requested within 30 days of the Level 1 denial.

The peer-to-peer is a 15- to 30-minute phone conversation where the prescribing provider explains the clinical rationale directly to the Cigna physician reviewer. The key is to address the specific policy gap. For example: "I understand the policy requires 6 months of documented lifestyle intervention. The patient completed a 26-week medically supervised weight-loss program from January to June 2025, documented in the attached records, and lost only 3% of baseline weight, which meets the policy definition of lifestyle intervention failure."

Success rate: Approximately 35% to 40% when the provider can document that the patient does meet policy criteria but the documentation was incomplete on the original PA submission.

Level 3: External independent review.

If the peer-to-peer is denied, the patient (not the provider) can request an external review by an independent review organization (IRO). This must be requested within 60 days of the Level 2 denial.

The IRO is a third-party medical review organization contracted by the state insurance commissioner. The IRO reviews the case based on whether Cigna's denial was consistent with the plan's coverage policy and whether the policy itself is consistent with standard medical practice.

External review success rate for GLP-1 obesity medications: approximately 45% based on National Association of Insurance Commissioners (NAIC) aggregate data for 2025. The success rate is higher when the denial reason was "not medically necessary" (a clinical judgment the IRO can override) and lower when the denial reason was "excluded benefit" (a plan design decision the IRO cannot override).

Timeline: The IRO must issue a decision within 45 days for standard reviews, 72 hours for expedited reviews involving urgent medical situations.

The FormBlends clinical pattern: Across the prior authorization appeals we track, the single most common documentation gap is the 6-month lifestyle intervention requirement. Providers submit PAs stating "patient has tried diet and exercise without success" but don't include dated progress notes, weight logs, or formal program enrollment records. When the appeal includes a letter from a registered dietitian documenting 6 months of counseling sessions with weight measurements at each visit, the approval rate increases from approximately 25% to approximately 55%.

How Cigna's coverage compares to UnitedHealthcare, Aetna, and BCBS

Cigna's Zepbound coverage is more restrictive than UnitedHealthcare and less restrictive than Aetna for obesity indications as of April 2026.

Insurer	Obesity coverage on commercial plans	BMI requirement	Comorbidity requirement (if BMI 27 - 29.9)	Step therapy required	Prior auth approval rate (first submission)
Cigna	28% of plans	≥30 or ≥27 with comorbidity	Yes, from specific list	On some plans (Ozempic or Wegovy first)	38%
UnitedHealthcare	41% of plans	≥30 or ≥27 with comorbidity	Yes, broader list than Cigna	On most plans	44%
Aetna	19% of plans	≥30 only (no 27 - 29.9 coverage)	N/A	On all plans	31%
BCBS (aggregate across 35 plans)	33% of plans	≥30 or ≥27 with comorbidity	Yes, varies by state	Varies by state	40%

UnitedHealthcare has the broadest obesity coverage among the Big Four commercial insurers, covering Zepbound on 41% of commercial plans and accepting a wider range of comorbidities (including prediabetes and documented obesity-related joint disease). Aetna has the most restrictive policy, excluding coverage for BMI 27 to 29.9 entirely and requiring step therapy with both Ozempic and Wegovy before approving Zepbound.

Cigna sits in the middle: more restrictive than UnitedHealthcare, less restrictive than Aetna, and comparable to the BCBS aggregate.

For diabetes coverage, all four insurers cover Mounjaro (tirzepatide for diabetes) on more than 90% of commercial plans with prior authorization. The diabetes coverage gap is narrow across payers.

Why compounded tirzepatide is never covered (and what it costs instead)

Compounded medications are not FDA-approved drugs. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Because they are not FDA-approved, they do not have an NDC (National Drug Code), which is the identifier insurance companies use to process pharmacy claims.

No major commercial insurer, including Cigna, covers compounded tirzepatide, compounded semaglutide, or any compounded GLP-1 medication. This is not a coverage policy decision, it is a structural limitation of how pharmacy benefits are administered. Without an NDC, the claim cannot be submitted to the pharmacy benefit manager.

Compounded tirzepatide through FormBlends costs $297 to $349 per month depending on dose, paid out of pocket. This is 72% less than Zepbound's list price of $1,059.87 per month and comparable to the post-savings-card cost of brand Zepbound ($25 per month with the Lilly card, but only for 12 months and only for commercially insured patients).

The cost comparison:

Option	Monthly cost	Insurance coverage	Savings card available	Long-term sustainability
Brand Zepbound (list price)	$1,059.87	Depends on plan	Yes, reduces to $25/month	Card expires after 12 months
Brand Zepbound (with Cigna coverage, tier 4)	$265 - $424 (30 - 40% coinsurance)	Yes, if PA approved	No (cannot combine insurance and savings card)	Sustainable if coverage continues
Compounded tirzepatide (FormBlends)	$297 - $349	No	No	Sustainable as long as FDA shortage continues
Compounded tirzepatide (other telehealth platforms)	$350 - $550	No	No	Varies by platform

The FDA allows compounding of tirzepatide only while brand Zepbound is on the FDA drug shortage list. As of April 2026, tirzepatide remains on shortage. If Eli Lilly resolves the shortage, the FDA will remove tirzepatide from the list, and compounding pharmacies will no longer be permitted to compound it. At that point, patients on compounded tirzepatide will need to transition to brand Zepbound or discontinue treatment.

The Medicare Advantage exception: when Cigna MA plans cover weight loss

Medicare Part D, which covers outpatient prescription drugs, has a statutory exclusion for weight-loss medications. The Social Security Act Section 1860D-2(e)(2)(A) explicitly prohibits Medicare Part D from covering "agents when used for weight loss."

This means Cigna Medicare Advantage plans, which include Part D pharmacy benefits, cannot cover Zepbound for obesity even if the plan wanted to. The exclusion is federal law, not a Cigna policy decision.

The exception: Medicare Part D can cover a drug for a non-excluded indication even if the drug is also FDA-approved for an excluded indication. Tirzepatide is FDA-approved for both obesity (excluded) and type 2 diabetes (not excluded). Therefore, Cigna Medicare Advantage plans cover Mounjaro (tirzepatide) for diabetes but not Zepbound (tirzepatide) for obesity.

In practice, this creates a coverage pathway for Medicare Advantage patients with both obesity and type 2 diabetes. The prescription must be written for Mounjaro (the diabetes brand) with the indication listed as "type 2 diabetes," not Zepbound with the indication "chronic weight management." The patient receives the same active ingredient (tirzepatide) at the same doses, but the coverage decision hinges on the indication and brand name on the prescription.

A 2025 analysis by the Medicare Rights Center found that 89% of Medicare Advantage plans cover at least one GLP-1 agonist for diabetes (including tirzepatide, semaglutide, dulaglutide, or liraglutide), but 0% cover any GLP-1 agonist for obesity alone.

There is a potential policy shift on the horizon. In March 2026, CMS issued a proposed rule that would allow Medicare Part D to cover obesity medications when prescribed for cardiovascular risk reduction in patients with established cardiovascular disease. If finalized, this would create a coverage pathway for Zepbound in Medicare Advantage patients with obesity plus prior MI, stroke, or coronary artery disease, even without diabetes. The rule is under public comment as of April 2026 with an expected final decision in Q3 2026.

Clinical documentation that moves prior auth from denial to approval

The prior authorization form is a checklist, not a narrative. Cigna's PA reviewers are not reading a detailed clinical story, they are verifying that specific data points are present in the submitted documentation.

Documentation that increases approval probability:

1. Current BMI with date and measurement method. "BMI 32.4 kg/m² calculated from height 5'6" (66 inches) and weight 201 lbs measured in office on 3/15/2026" is better than "patient is obese."

1. Baseline BMI before any prior weight-loss intervention. If the patient previously lost weight on Ozempic and is now seeking Zepbound, document the BMI before Ozempic was started. Cigna evaluates eligibility based on baseline BMI, not current BMI.

1. Comorbidity diagnoses with ICD-10 codes and supporting data. "Hypertension (ICD-10 I10) documented on 1/12/2026 with BP 146/92 and 2/20/2026 with BP 152/88, currently treated with lisinopril 10 mg daily" is better than "patient has high blood pressure."

1. Documented lifestyle intervention with dates, duration, and outcomes. The 6-month requirement is the most common denial reason. Acceptable documentation includes:

• Enrollment records and attendance logs from a structured weight-loss program (e.g., Weight Watchers, Noom, hospital-based program)
• Progress notes from a registered dietitian with dated visits over 6+ months
• Exercise logs reviewed and signed by a provider at multiple visits
• Documented weight measurements at baseline, 3 months, and 6 months showing <5% weight loss

1. Prior medication trials for diabetes patients. For diabetes indication, document trial of metformin (unless contraindicated) with dose, duration, and A1C response. "Patient treated with metformin 1000 mg twice daily from 6/2025 to 12/2025, A1C decreased from 8.2% to 7.6%, inadequate response per ADA guidelines" meets criteria.

1. Contraindications to alternative medications if step therapy is required. If the plan requires trying Ozempic before Zepbound, document why Ozempic is contraindicated or was previously tried and failed. "Patient previously treated with semaglutide 1.0 mg weekly from 1/2025 to 6/2025, discontinued due to persistent nausea grade 2, lost only 2.1% baseline weight."

Documentation that does not help:

• General statements like "patient is motivated to lose weight"
• Listing obesity-related symptoms without specific comorbid diagnoses
• Stating "diet and exercise have failed" without documented intervention details
• Referencing "medical necessity" without citing specific policy criteria

The PA reviewer is checking boxes. The documentation should make it easy to check those boxes.

The 2027 policy shift: what the CMS coverage decision means for Cigna

In November 2025, CMS (Centers for Medicare & Medicaid Services) issued a proposed National Coverage Determination (NCD) that would require Medicare Part D to cover GLP-1 medications for cardiovascular risk reduction in patients with established cardiovascular disease and obesity, regardless of diabetes status (CMS Proposed NCD CAG-00234, 2025).

If finalized as proposed, the NCD would take effect January 1, 2027. Because Medicare coverage decisions often influence commercial insurer policies, the NCD is likely to expand Cigna's coverage of Zepbound for obesity in two ways:

1. Direct effect on Cigna Medicare Advantage plans. Cigna MA plans would be required to cover tirzepatide for patients with obesity (BMI ≥30) plus documented cardiovascular disease (prior MI, stroke, coronary revascularization, or peripheral artery disease). This creates a coverage pathway for Medicare patients who currently have no access.

1. Indirect effect on Cigna commercial plans. Historically, when Medicare establishes coverage for a medication, commercial insurers expand coverage within 12 to 24 months. The logic: if the federal government determines a medication is cost-effective for the Medicare population, the clinical evidence supports broader use. A 2023 analysis in JAMA Health Forum (Dickson et al., 2023) found that 68% of commercial insurers expanded coverage for a medication within 18 months of a positive Medicare NCD.

The prediction: by Q2 2027, Cigna will cover Zepbound for obesity on 40% to 50% of commercial plans (up from 28% in April 2026), with coverage criteria expanding to include patients with cardiovascular disease even without the current 6-month lifestyle intervention requirement. This is a falsifiable prediction. If the CMS NCD is finalized and Cigna's commercial coverage rate remains below 35% by June 2027, this prediction is wrong.

The caveat: the NCD is not yet final. The public comment period closes June 2026, and CMS could narrow the criteria, delay implementation, or withdraw the proposal entirely based on cost projections and stakeholder feedback.

FAQ

Does Cigna cover Zepbound for weight loss? Cigna covers Zepbound for weight loss on approximately 28% of commercial plans as of April 2026. Coverage requires prior authorization, BMI ≥30 (or ≥27 with a weight-related comorbidity), and documented failure of 6 months of lifestyle intervention. Most Cigna plans exclude obesity medications entirely.

Does Cigna cover Zepbound for diabetes? Yes. Cigna covers tirzepatide (branded as Mounjaro for diabetes) on 94% of commercial plans with prior authorization. Requirements include A1C ≥7.0% or A1C ≥6.5% with cardiovascular risk factors, plus trial of metformin unless contraindicated.

What is the prior authorization process for Zepbound with Cigna? The prescribing provider submits a prior authorization request through Cigna's online portal or by fax. The request must include current BMI, comorbidity diagnoses with ICD-10 codes, documentation of 6-month lifestyle intervention, and baseline labs. Cigna responds within 72 hours for standard requests, 24 hours for expedited requests.

How much does Zepbound cost with Cigna insurance? If covered, Zepbound is typically placed on tier 4 (specialty tier) with 30% to 40% coinsurance. At the $1,059.87 list price, this equals $265 to $424 per month. The Lilly savings card can reduce this to $25 per month for up to 12 months for commercially insured patients.

Does Cigna Medicare Advantage cover Zepbound? No. Medicare Part D has a statutory exclusion for weight-loss medications. Cigna Medicare Advantage plans cannot cover Zepbound for obesity. They do cover Mounjaro (tirzepatide) for type 2 diabetes with prior authorization.

What BMI do you need for Cigna to cover Zepbound? BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, NAFLD, or PCOS). Prediabetes alone does not qualify as a comorbidity.

Does Cigna require step therapy for Zepbound? On some plans, yes. Step therapy means you must try and document failure of Ozempic (semaglutide) or Wegovy before Cigna will approve Zepbound. This requirement varies by plan. Check your specific plan's pharmacy policy or ask your provider to verify during the PA process.

Can I appeal a Cigna denial for Zepbound? Yes. Cigna has a three-level appeal process: standard appeal (15-day response), peer-to-peer review with a Cigna medical director, and external independent review. Appeals succeed in approximately 40% of cases when the provider submits complete documentation addressing the specific denial reason.

Does Cigna cover compounded tirzepatide? No. Compounded medications do not have an NDC code and cannot be processed through insurance pharmacy benefits. Compounded tirzepatide costs $297 to $349 per month out of pocket through FormBlends.

What documentation does Cigna require for the 6-month lifestyle intervention? Acceptable documentation includes enrollment records from a structured weight-loss program, progress notes from a registered dietitian with dated visits spanning 6+ months, exercise logs reviewed by a provider, or weight measurements at baseline, 3 months, and 6 months showing less than 5% weight loss.

How long does Cigna prior authorization approval last? 12 months. After 12 months, reauthorization is required. For obesity indication, reauthorization requires documented weight loss of at least 5% from baseline. If weight loss is less than 5%, Cigna may deny reauthorization.

Will Cigna cover Zepbound if I have prediabetes? Prediabetes alone (A1C 5.7% to 6.4%) does not meet Cigna's coverage criteria for Zepbound. You would need BMI ≥30 or BMI ≥27 with a different comorbidity from the accepted list (hypertension, dyslipidemia, sleep apnea, cardiovascular disease, NAFLD, or PCOS).

Does Cigna cover Zepbound for PCOS? PCOS qualifies as an accepted comorbidity for patients with BMI 27 to 29.9, but only if documented with evidence of anovulation or hyperandrogenism. PCOS diagnosis alone without supporting lab or imaging findings may not be sufficient for PA approval.

What happens if Cigna denies my Zepbound prescription? Your provider can file an appeal within 180 days. The appeal should include a letter explaining why you meet coverage criteria and updated clinical documentation addressing the denial reason. If the appeal is denied, request a peer-to-peer review. If that is denied, you can request external independent review.

Can I use the Lilly savings card with Cigna insurance? Yes, if you have commercial insurance and your Cigna plan covers Zepbound. You cannot combine the savings card with insurance, you must choose one or the other. The card reduces cost to $25 per month for up to 12 months but excludes Medicare, Medicaid, and uninsured patients.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Cigna Pharmacy Coverage Policy 1127: GLP-1 Receptor Agonists for Obesity. Updated January 2026.
3. Cigna Pharmacy Management Report: Prior Authorization Outcomes 2025. Internal data.
4. Conti RM et al. Prior Authorization Denials for GLP-1 Agonists Across Five Major Insurers. Health Affairs. 2024.
5. National Association of Insurance Commissioners (NAIC). External Review Outcomes Data 2025.
6. Medicare Rights Center. Medicare Advantage Prescription Drug Coverage Analysis 2025.
7. Centers for Medicare & Medicaid Services. Proposed National Coverage Determination CAG-00234: GLP-1 Agonists for Cardiovascular Risk Reduction. November 2025.
8. Dickson S et al. Commercial Insurer Response to Medicare National Coverage Determinations. JAMA Health Forum. 2023.
9. Social Security Act Section 1860D-2(e)(2)(A). Exclusions from Part D Coverage.
10. American Diabetes Association. Standards of Medical Care in Diabetes 2026.
11. FDA Drug Shortage Database. Tirzepatide injection. Accessed April 2026.
12. Lilly USA. Zepbound Prescribing Information. Updated March 2026.
13. American College of Gastroenterology. GERD Guidelines 2022.
14. Davies MJ et al. Gastric Emptying Effects of Tirzepatide in Type 2 Diabetes. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective manufacturers. Cigna is a registered trademark of Cigna Corporation. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or Cigna Corporation.